Christopher E Brightling
Overview
Explore the profile of Christopher E Brightling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
263
Citations
11027
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shergill S, Elshibly M, Hothi S, Parke K, England R, Wormleighton J, et al.
BMJ Open
. 2025 Mar;
15(3):e089508.
PMID: 40050066
Introduction: SARS-CoV-2 disease (COVID-19) has had an enormous health and economic impact globally. Although primarily a respiratory illness, multi-organ involvement is common in COVID-19, with evidence of vascular-mediated damage in...
2.
Martin N, Wechsler M, Brightling C
Eur Respir J
. 2025 Feb;
65(2).
PMID: 39947687
No abstract available.
3.
Castro M, Papi A, Porsbjerg C, Lugogo N, Brightling C, Gonzalez-Barcala F, et al.
Lancet Respir Med
. 2025 Feb;
13(3):208-220.
PMID: 39947221
Background: Asthma is a respiratory disease characterised by chronic airway inflammation and mucus hypersecretion. VESTIGE used functional respiratory imaging to assess changes in airway structure and function, including mucus plugging,...
4.
Brightling C, Marone G, Aegerter H, Chanez P, Heffler E, Pavord I, et al.
Eur Respir Rev
. 2024 Dec;
33(174.
PMID: 39694589
The Epithelial Science Expert Group convened on 18-19 October 2023, in Naples, Italy, to discuss the current understanding of the fundamental role of the airway epithelium in asthma and other...
5.
Lee P, Guyatt A, John C, Ali A, Wang X, Williams A, et al.
Wellcome Open Res
. 2024 Dec;
6:349.
PMID: 39669688
New data collection in established longitudinal population studies provides an opportunity for studying the risk factors and sequelae of the novel coronavirus disease 2019 (COVID-19), plus the indirect impacts of...
6.
Singh D, Brightling C, Rabe K, Han M, Christenson S, Drummond M, et al.
Lancet Respir Med
. 2024 Dec;
13(1):47-58.
PMID: 39653044
Background: Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, which has shown increased expression in patients with chronic obstructive pulmonary disease (COPD) compared with healthy individuals. We...
7.
van Boven J, Costello R, Roes K, Brusselle G, Hansen K, Krishnan J, et al.
Lancet Respir Med
. 2024 Dec;
13(2):177-188.
PMID: 39647486
Digital technologies (eg, smart inhalers, wearables, and sensors) allow for remote, objective, granular, and non-invasive data collection, making them attractive for research evaluating interventions in airways diseases with variable trajectories,...
8.
Tyrer F, Gharibzadeh S, Gillies C, Lawson C, Routen A, Islam N, et al.
Diabetes Obes Metab
. 2024 Nov;
27(2):767-776.
PMID: 39563623
Background: People hospitalised for coronavirus disease 2019 (COVID-19) have elevated incidence of diabetes. However, it is unclear whether this is due to shared risk factors, confounding or stress hyperglycaemia in...
9.
Elneima O, McAuley H, Leavy O, Chalmers J, Horsley A, Ho L, et al.
Int J Epidemiol
. 2024 Oct;
53(1).
PMID: 39429158
No abstract available.
10.
Aung H, Aung A, McAuley H, Elneima O, Flynn C, Thornton T, et al.
ERJ Open Res
. 2024 Oct;
10(5).
PMID: 39351391
https://bit.ly/3wN71h0.